NM_000329.3(RPE65):c.272G>C (p.Arg91Pro) is a missense variant predicted to replace arginine with proline at amino acid p.91. This residue is a well-characterized functional site that forms a salt bridge with glutamate 127 that is reportedly required for correct positioning of membrane-binding elements that mediate localization to the ER membrane (PMID: 19805034, PM1). Another missense variant in the same codon, NM_000329.3(RPE65):c.272G>A (p.Arg91Gln), has been classified as pathogenic for RPE65-related recessive retinopathy by the ClinGen LCA / eoRD VCEP. However, splicing prediction using SpliceAI indicated a likely splicing defect due to NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) (score of 0.21 for acceptor loss) that was not predicted for the present variant (with a score of 0.12 for acceptor gain), so the PM5 code was not met. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.430T>G (p.Tyr144Asp) variant confirmed in trans (1 point, PMID: 17724218) which was previously classified likely pathogenic by the ClinGen LCA / eoRD VCEP (1 total point, PM3). The variant has also been reported in a second proband with early-onset severe retinal dystrophy who was compound heterozygous with the NM_000329.3(RPE65):c.65T>C (p.Leu22Pro) variant suspected in trans (PMID: 32865313), which was not included in the PM3 code. At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts), light-gazing (1 pt), visual acuity limited to light perception (1 pt), nystagmus (1 pt), extinguished ERG responses from both rods (0.5 pts) and cones (1 pt), salt-and-pepper fundus (0.5 pts) with macular atrophy (0.5 pts), and absence of fundus autofluorescence (2 pts), which together are highly specific for RPE65-related recessive retinopathy (total 8 points, PMID: 17724218, PP4_Moderate). The computational predictor REVEL gives a score of 0.766, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.644 and predicts a damaging effect on RPE65 function (PP3). The splicing impact predictor SpliceAI gives a score of 0.12 for acceptor gain, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing. In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM1, PM2_Supporting, PM3, PP3, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).